Evidence map›Paper›PMID 42319401›Full record

ArticleClinical and experimental medicine2026

Decoding chromatin regulator-LAIR1

Chuanqi Zhang, Bo Chen, Zhe Li, Xianwei Li, Weiliang Jiang

Abstract read
In one paragraph

Article in Clinical and experimental medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Chuanqi ZhangDepartment of Vascular Surgery, the Second Affiliated Hospital of Harbin Medical University, Harbin, 150001, P.R. China.
Bo ChenDepartment of Vascular Surgery, the Second Affiliated Hospital of Harbin Medical University, Harbin, 150001, P.R. China.
Zhe LiDepartment of Vascular Surgery, the Second Affiliated Hospital of Harbin Medical University, Harbin, 150001, P.R. China.
Xianwei LiDepartment of Vascular Surgery, the Second Affiliated Hospital of Harbin Medical University, Harbin, 150001, P.R. China.
Weiliang JiangDepartment of Vascular Surgery, the Second Affiliated Hospital of Harbin Medical University, Harbin, 150001, P.R. China. weiliangj_hrb@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Atherosclerosis (AS) is a common complication of lung adenocarcinoma (LUAD), but its underlying mechanisms in LUAD remain unclear. This study aimed to decipher the role of chromatin regulators in AS pathogenesis and their association with clinical outcomes in LUAD patients. AS- and chromatin regulator (CR)-associated prognostic indicators were identified in LUAD and analyzed in the TCGA-LUAD cohort using Cox regression and Disease Ontology analysis. CR-related risk subgroups were defined by NMF in the GSE26939 cohort. GSVA and WGCNA, combined with interpretable machine learning, were used to construct a predictive model and identify key genes, which were validated in GSE68465. The molecular features of key genes and their roles in AS were further evaluated. Besides, mechanisms of key genes in M2-like macrophages were assessed at the single-cell level in LUAD patients using cutting-edge analytical frameworks. A deep learning framework and molecular docking were used to screen natural compounds. Finally, co-culture experiments were conducted for validation. CR signatures can guide the LUAD patients LUAD patients into high- and low-AS risk groups and were associated with clinical outcomes. LAIR1 can be considered as an AS-related factor enriched in M2-like macrophages and involved in LUAD progression. Quercetin was identified as potential preventive agent for AS in LUAD patients. CR-associated signatures play an important role in AS pathogenesis and LUAD progression.

Indexed as

Adenocarcinoma of LungAtherosclerosisLung NeoplasmsMacrophagesArtificial IntelligenceFemaleHumansMalePrognosisArtificial intelligenceAtherosclerosisChromatin regulatorLung adenocarcinomaM2 like macrophageMulti-omics

Identifiers

PMID42319401
PMCPMC13526722

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.